AtriCure (ATRC) Misses Q1 EPS by 3c ; Offers Guidance
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $34.28 -0.81%
EPS Growth %: +92.3%
Financial Fact:
Interest income: 67K
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: +92.3%
Financial Fact:
Interest income: 67K
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q1 EPS of ($0.25), $0.03 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $108.9 million versus the consensus estimate of $106.91 million.
GUIDANCE:
AtriCure sees FY2024 EPS of ($0.74)-($0.82), versus the consensus of ($0.76). AtriCure sees FY2024 revenue of $459-466 million, versus the consensus of $461.2 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
- Ionis Pharmaceuticals (IONS) reaffirms guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
